Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions in China, has announced that it has received marketing approval from the National Medical Products Administration for its innovative product, NeoGlu 01, a noninvasive blood glucose meter. This new device combines optical and thermal methods to collect physiological and environmental signals related to blood glucose levels, utilizing software algorithms, big data analysis, and artificial intelligence to predict changes in blood glucose.
NeoGlu 01 is designed to estimate glucose concentration in adults in a noninvasive manner, offering a tool for daily blood glucose management for type 2 diabetes patients who are not on insulin treatment. While this product can complement existing fingertip blood glucose monitoring methods, it is not intended to replace other blood glucose monitoring methods. Patients are still advised to regularly collect fingertip blood samples for glucose measurement to ensure accurate diabetes management.- Flcube.com
